Form 4: UTHR Director Sells Shares After Option Exercise

United Therapeutics Director Christopher Causey exercised stock options and subsequently sold 1,000 shares of common stock for $510 per share under a pre-arranged 10b5-1 plan.

Summary

• Christopher Causey, a Director at United Therapeutics Corp (UTHR), engaged in a pre-planned transaction on January 6, 2026.
• The transaction involved the exercise of 1,000 stock options at an exercise price of $119.76 per share.
• Immediately following the exercise, 1,000 shares of common stock were sold at a price of $510 per share.
• This exercise and sale were conducted pursuant to a Rule 10b5-1 trading plan established by Mr. Causey on September 30, 2025.
• After these transactions, Mr. Causey beneficially owns 4,190 shares of common stock directly.
• Additionally, Mr. Causey beneficially owns 7,320 derivative securities (stock options) directly, with an exercise price of $119.76, exercisable from June 26, 2021, and expiring on June 26, 2030.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale under a 10b5-1 plan, which is a routine event and does not inherently signal strong positive or negative sentiment regarding the company's immediate prospects.

Positives

• The director realized a significant gain by exercising options at $119.76 and selling shares at $510, reflecting a substantial increase in the company's stock value since the option grant.

Negatives

• An insider selling shares, even under a pre-arranged plan, reduces their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to a director's personal trading activity and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may note the director's reduction in direct equity ownership, though the pre-planned nature of the transaction typically mitigates concerns about immediate sentiment.

Key Dates

Recommendation

The transaction represents a pre-scheduled exercise of stock options and subsequent sale of shares by a director under a Rule 10b5-1 trading plan. Such pre-arranged sales are generally considered routine and do not typically indicate a change in the company's fundamental outlook or warrant an immediate shift in investment recommendation.

Keywords

UTHR, United Therapeutics, Form 4, Insider Transaction, Stock Options, Director, Share Sale, 10b5-1 Plan